{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:44Z","timestamp":1780586084674,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01760-8","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:57:02Z","timestamp":1777003022000},"page":"3027-3036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-6350","authenticated-orcid":false,"given":"Francesco","family":"Piscazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3089-4362","authenticated-orcid":false,"given":"Giovanni","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-1220","authenticated-orcid":false,"given":"Riccardo G.","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"1760_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1760_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1760_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1365-2133.2004.06093.x","volume":"151","author":"F Sampogna","year":"2004","unstructured":"Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151:594\u20139.","journal-title":"Br J Dermatol"},{"key":"1760_CR4","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0190-9622(03)01136-8","volume":"49","author":"J Choi","year":"2003","unstructured":"Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49:S57-61.","journal-title":"J Am Acad Dermatol"},{"key":"1760_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2340\/00015555-1273","volume":"92","author":"F Sampogna","year":"2012","unstructured":"Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92:299\u2013303.","journal-title":"Acta Derm Venereol"},{"key":"1760_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1440-0960.2004.00078.x","volume":"45","author":"PA Russo","year":"2004","unstructured":"Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45:155\u20139 (quiz 60-1).","journal-title":"Australas J Dermatol"},{"key":"1760_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, et\u00a0al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet"},{"key":"1760_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164623","author":"G Ghezzi","year":"2024","unstructured":"Ghezzi G, Costanzo A, Borroni RG. Health-related quality of life in psoriasis: literature review. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13164623.","journal-title":"J Clin Med"},{"key":"1760_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, Pu\u00edg L, Reich K, van de Kerkhof P, et\u00a0al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatol Ther (Heidelb). 2022;12:61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1760_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, Stein Gold L, Flower A, Jardon S, et\u00a0al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther. 2023;13:1329\u201346.","journal-title":"Dermatol Ther"},{"key":"1760_CR11","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","volume":"33","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, et\u00a0al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33:2305\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1760_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jdv.19468","volume":"37","author":"S Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Herranz-Pinto P, Ru\u00edz-Villaverde R, L\u00f3pez-Ferrer A, Santos-Juanes J, et\u00a0al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37:2517\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1760_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/ced\/llae433","volume":"50","author":"S Cacciapuoti","year":"2025","unstructured":"Cacciapuoti S, Battista T, Potestio L, Scalvenzi M, Megna M, Ruggiero A. Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study. Clin Exp Dermatol. 2025;50:544\u201350.","journal-title":"Clin Exp Dermatol"},{"key":"1760_CR14","doi-asserted-by":"crossref","unstructured":"G. Licata, E.V. Di Brizzi, F. Castelli, G. Giuffrida, E. Stroppiana, A. Dattola, et\u00a0al. Tildrakizumab and quality of life: deep dive into the impact of psoriasis and treatment on different domains\u2014should psychosocial life impairment be considered a comorbidity? J Clin Med. 14 (2025).","DOI":"10.3390\/jcm14010223"},{"key":"1760_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/1346-8138.16517","volume":"49","author":"H Saeki","year":"2022","unstructured":"Saeki H, Kanai Y, Murotani K, Ito K, Miyagi T, Takahashi H, et\u00a0al. Work productivity in real-life employed patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol. 2022;49:970\u20138.","journal-title":"J Dermatol"},{"key":"1760_CR16","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","volume":"66","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, et\u00a0al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66:e67-76.","journal-title":"J Am Acad Dermatol"},{"key":"1760_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41:514\u201321.","journal-title":"Clin Exp Dermatol"},{"key":"1760_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.18798","volume":"183","author":"R Villacorta","year":"2020","unstructured":"Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183:548\u201358.","journal-title":"Br J Dermatol"},{"key":"1760_CR19","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1991","volume":"102","author":"B Halioua","year":"2022","unstructured":"Halioua B, Chelli C, Misery L, Taieb J, Taieb C. Sleep disorders and psoriasis: an update. Acta Derm Venereol. 2022;102:adv00699.","journal-title":"Acta Derm Venereol"},{"key":"1760_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.674460","volume":"12","author":"J Nowowiejska","year":"2021","unstructured":"Nowowiejska J, Baran A, Flisiak I. Mutual relationship between sleep disorders, quality of life and psychosocial aspects in patients with psoriasis. Front Psychiatry. 2021;12:674460.","journal-title":"Front Psychiatry"},{"key":"1760_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44757-5","volume":"13","author":"MS Zaky","year":"2023","unstructured":"Zaky MS, Elgamal EEA, Abd Al Maksoud AA, Mohamed DH, Elsaie ML. Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study. Sci Rep. 2023;13:17541.","journal-title":"Sci Rep"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01760-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:46Z","timestamp":1780584826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01760-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1760"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01760-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, Abbvie, La Roche-Posay, and Pfizer. Francesco Piscazzi has no conflict of interest to declare. Giovanni Fiorillo has served as consultant and\/or speaker for Novartis, LeoPharma, Bristol Meyer Squibb, Incyte, and Eli Lilly. Mario Valenti has served as consultant and\/or speaker for Novartis, Almirall, Eli-Lilly, Abbvie, Johnson&Johnson, UCB, Boehringer-Ingelheim, Difa Cooper, Sun-Pharma, Leo Pharma, and Bristol Myers Squibb. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Eli-Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB. Riccardo G. Borroni has served as consultant in scientific board for Almirall and Istituto Gentili.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board (protocol no. 3083) and conducted in accordance to the Helsinki Declaration of 1964. All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}